Vigil Neuroscience, Inc.

VIGL

US92673K1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:14:37 2024-05-28 pm EDT			5-day change	1st Jan Change
3.44 ^USD	-5.23%		-3.43%	0.00%

May. 07	Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	CI

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	Apr. 17	CI
Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating	Mar. 26	MT
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	Mar. 20	MT
Vigil Neuroscience, Inc. Announces Executive Changes	Mar. 20	CI
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Transcript : Vigil Neuroscience, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
North American Morning Briefing : S&P 500 Futures -2-	Dec. 20	DJ
Morgan Stanley Downgrades Vigil Neuroscience to Underweight From Equalweight, Cuts Price Target to $4 From $13	Dec. 19	MT
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia	Nov. 16	MT
Transcript : Vigil Neuroscience, Inc. - Special Call	Nov. 16
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	Nov. 16	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
JMP Securities Starts Vigil Neuroscience With Market Outperform Rating, Price Target is $23	23-10-18	MT
Vigil Neuroscience Shares Rise After First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment	23-10-17	MT
Vigil Neuroscience Says First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment	23-10-17	MT
Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease	23-10-17	CI
Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927	23-10-12	CI
Vigil Says Orphan Drug Designation Application for Proposed Leukoencephalopathy Therapy Secured European Positive Opinion	23-09-26	MT
Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP	23-09-26	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) added to S&P Global BMI Index	23-09-18	CI
Transcript : Vigil Neuroscience, Inc. - Special Call	23-09-13

Chart Vigil Neuroscience, Inc.

Duration

Period

More charts

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimerâs disease in genetically defined subpopulations.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.63 USD

Average target price

16.75 USD

Spread / Average Target

+361.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIGIL NEUROSCIENCE, INC.	+0.30%	136M
MODERNA, INC.	+51.39%	63.85B
IQVIA HOLDINGS INC.	-2.51%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.39%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.59%	18.69B
BIO-TECHNE CORPORATION	+2.62%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.06%	12.11B
MEDPACE HOLDINGS, INC.	+27.89%	12.07B

Other Biotechnology & Medical Research